Theories of endometrial carcinogenesis: A multidisciplinary approach

Modern Pathology

Volumn 13, Issue 3, 2000, Pages 295-308

  Sherman, Mark E ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

Carcinogenesis; Carcinoma; Endometrioid; Endometrium; Epidemiology; Pathology; Sero us

Indexed keywords

ESTROGEN; HORMONE RECEPTOR; PROTEIN P53;

ADENOCARCINOMA; ARTICLE; CANCER RISK; CARCINOGENESIS; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; FEMALE; GENE MUTATION; HUMAN; MICROSATELLITE INSTABILITY; ONCOGENE RAS; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

EID: 0034083599     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: 10.1038/modpathol.3880051     Document Type: Article

References (69)

1. Sherman ME, Bur ME, Kurman RJ. p53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigenesis. Hum Pathol 1995;26:1268-74.
2. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983;15:10-7.
3. Parker SL, Tong T, Bolden, Wingo PA. Cancer statistics, 1996. CA Cancer J Clin 1996;65:5-27.
4. Grady D, Ernster VL. Endometrial cancer. In: Schottenfeld D, Fraumeni JF Jr, editors. Cancer epidemiology and prevention. 2nd ed. New York: Oxford University Press; 1996. p. 1058-89.
5. Barrett RJ II, Harlan LC, Wesley MN, Hill Ha, Chen VW, Clayton LA, et al. Endometrial cancer: stage at diagnosis and associated factors in black and white patients. Am J Obstet Gynecol 1995;173:414-23.
6. Hicks ML, Kim W, Abrams J, Johnson CC, Blount AC, Parham GP. Racial differences in surgically staged patients with endometrial cancer. J Natl Med Assoc 1997;89:134-40.
7. Hill HA, Eley JW, Harlan LC, Greenberg RS, Barrett RJ, Chen VW. Racial differences in endometrial cancer survival: the black/white cancer survival study. Obstet Gynecol 1996;88: 919-26.
8. Liu JR, Conaway M, Rodriguez GC, Soper JT, Clarke-Pearson DL, Berchuck A. relationship between race and interval to treatment in endometrial cancer. Obstet Gynecol 1995;86: 486-90.
9. Sherman ME, Sturgeon S, Brinton LA, Potischman N, Kurman RJ, Berman ML, et al. Risk factors and hormone levels in patients with serous and endometrioid uterine carcinomas. Mod Pathol 1997;10:963-8.
10. Potischman N, Hoover RN, Brinton LA, Siiteri P, Dorgan JF, Swanson CA, et al. A case-control study of endogenous steroid hormones and endometrial cancer. J Natl Cancer Inst 1996;88:1127-35.
11. Sturgeon SR, Sherman ME, Kurman RJ, Berman ML, Mortel R, Twiggs LB, et al. Analysis of histopathological features of endometrioid uterine carcinomas and epidemiologic risk factors. Cancer Epidemiol Biomarkers Prev 1998;7:231-5.
12. Hendrickson M, Ross J, Eifel P, Cox RS, Martinez A, Kempson R. Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma. Am J Surg Pathol 1982;6:93-108.
13. Sherman ME, Bitterman P, Rosenshein NB, Delgado G, Kurman RJ. Uterine serous carcinoma: a morphologically diverse neoplasm with unifying clinicopathologic features. Am J Surg Pathol 1992;16:600-10.
14. Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia. A long-term study of "untreated" hyperplasia in 170 patients. Cancer 1985;56:403-12.
15. Randall TC, Kurman RJ. Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40. Obstet Gynecol 1997;90:434-40.
16. Kim YB, Holschneider CH, Ghosh K, Nieberg RK, Montz FJ. Progestin alone as primary treatment of endometrial carcinoma in premenopausal women. Report of seven cases and review of the literature. Cancer 1997;320-7.
17. Ferenczy A, Gelfand M. The biologic significance of cytologic atypia in progestogen-treated endometrial hyperplasia. Am J Obstet Gynecol 1989;160:126-31.
18. Ambros RA, Sherman ME, Zahn CM, Bitterman P, Kurman RJ. Endometrial intraepithelial carcinoma: a distinctive lesion specifically associated with tumors displaying serous differentiation. Hum Pathol 1995;26:1260-7.
19. Carcangiu ML, Chambers JT. Uterine papillary serous carcinoma: a study of 108 cases with emphasis on the prognostic significance of associated endometrioid carcinoma, absence of invasion, and concomitant ovarian carcinoma. Gynecol Oncol 1992;47:298-305.
20. Spiegel GW. Endometrial carcinoma in situ in postmenopausal women. Am J Surg Pathol 1995;19:417-32.
21. Zheng W, Khurana R, Farahmand S, Wang Y, Zhang Z, Felix JC. p53 immunostaining as a significant adjunct diagnostic method for uterine surface carcinoma. Am J Surg Pathol 1998;22:163-73.
22. Tashiro H, Isacson C, Levine R, Kurman RJ, Cho KR, Hedrick L. p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis. Am J Pathol 1997;150:177-85.
23. Lee KR, Belinson JL. Recurrence in noninvasive endometrial carcinoma. Am J Surg Pathol 1991;15:965-73.
24. Goff BA, Kata D, Schmidt RA. Uterine papillary serous carcinoma: patterns of metastatic spread. Gynecol Oncol 1994; 54:264-8.
25. Silva EG, Jenkins R. Serous carcinoma in endometrial polyps. Mod Pathol 1990;3:120-8.
26. Ambros RA, Ross JS, Kallakury BV, Malfetano J, Kim Y, Hwang J, et al. p53 gene status in endometrial carcinomas showing diffuse positivity for p53 protein by immunohistochemical analysis. Mod Pathol 1995;8:441-5.
27. Ambros RA, Sheehan CE, Kallakury BV, Ross JS, Malfetano J, Paunovich E, et al. MDM2 and p53 protein expression in the histologic subtypes of endometrial carcinoma. Mod Pathol 1996;9:1165-9.
28. Bur ME, Perlman C, Edelman L. p53 expression in neoplasms of the uterine corpus. Am J Clin Pathol 1992;98:81-7.
29. Ito K, Sasano H, Matsunaga G, Sato S, Yajima A, Nasim S, et al. Correlations between p21 expression and clinicopathologic findings, p53 gene and protein alterations, and survival in patients with endometrial carcinoma. J Pathol 1997;183: 318-24.
30. Jiko K, Sasano H, Ito K, Ozawa N, Sato S, Yajima A. Immunohistochemical, and in situ hybridization analysis of p53 in human endometrial carcinoma of the uterus. Anticancer Res 1993;13:305-10.
31. King SA, Adas AA, LiVolsi VA, Takahashi H, Behbakht K, McGovern P, et al. Expression and mutation analysis of the p53 gene in uterine papillary serous carcinoma. Cancer 1995;75:2700-5.
32. Kohler MF, Nishii H, Humphrey PA, Saski H, Marks J, Bast RC, et al. Mutation of the p53 tumor-suppressor gene is not a feature of endometrial hyperplasia. Am J Obstet Gynecol 1993;169:690-4.
33. Kohler MF, Berchuck A, Davidoff AM, Humphrey PA, Dodge RK, Iglehart JD, et al. Overexpression and mutation of p53 in endometrial carcinoma. Cancer Res 1992;52:1622-7.
34. Moll UM, Chalas E, Auguste M, Meaney D, Chumas J. Uterine papillary serous carcinoma evolves via a p53-driven pathway. Hum Pathol 1996;27:1295-300.
35. Soslow RA, Shen PU, Chung MH, Isacson C. Distinctive p53 and mdm2 immunohistochemical expression profiles suggest different pathogenetic pathways in poorly differentiated endometrial carcinoma. Int J Gynecol Pathol 1998;17:129-34.
36. Hussain SP, Harris CC. Molecular epidemiology of human cancer: contribution of mutation spectra studies of tumor suppressor genes. Cancer Res 1998;58:4023-37.
37. Eschelman JR, Markowitz SD. Microsatellite instability in inherited and sporadic neoplasms. Curr Opin Oncol 1995;7:83-9.
38. Loeb LA. Microsatellite instability: marker of a mutator phenotype in cancer. Cancer Res 1994;54:5059-63.
39. Burks RT, Kessis TD, Cho KE, Hedrick L. Microsatellite instability in endometrial carcinoma. Oncogene 1994;11:1163-6.
40. Caduff RF, Johnston CM, Svoboda-Newman SM, Poy EL, Merajver SD, Frank TS. Clinical and pathological significance of microsatellite instability in sporadic endometrial carcinoma. Am J Pathol 1996;148:1671-8.
41. Duggan BD, Felix JC, Muderspach LI, Tourgeman D, Zheng J, Shibata D. Microsatellite instability in sporadic endometrial carcinoma. J Natl Cancer Inst 1994;86:1216-21.
42. Mutter GL, Boynton KA, Faquin WC, Ruiz RE, Jovanovic AS. Allelotype mapping of unstable microsatellites establishes direct lineage continuity between endometrial precancers and cancer. Cancer Res 1996;56:4483-6.
43. Peiffer SL, Herzog TJ, Tribune DJ, Mutch DG, Gersell DJ, Goodfellow PJ. Allelic loss of sequences from the long arm of chromosome 10 and replication errors in endometrial cancers. Cancer Res 1995;55:1922-6.
44. Risinger JI, Berchuck A, Kohler MF, Watson P Lynch HT, Boyd J. Genetic instability of microsatellites in endometrial carcinoma. Cancer Res 1993;53:5100-3.
45. Tashiro H, Lax SF, Gaudin PB, Isacson C, Cho KR, Hedrick L. Microsatellite instability is uncommon in uterine serous carcinoma. Am J Pathol 1997;150:75-9.
46. Catasus L, Machin P, Matias-Guiu X, Prat J. Microsatellite instability in endometrial carcinomas. Clinicopathologic correlations in a series of 42 cases. Hum Pathol 1998;29: 1160-4.
47. Gurin CC, Federici MG, Kang L, Boyd J. Causes and consequences of microsatellite instability in endometrial carcinoma. Cancer Res 1999;59:462-6.
48. Levine RL, Cargile CB, Blazes MS, van Rees B, Kurman RJ, Ellenson LH. PTEN mutations and microsatellite instability in complex atypical hyperplasia, a precursor lesion to uterine endometrioid carcinoma. Cancer Res 1998;58:3524-8.
49. Maxwell GL, Risinger JI, Gumbs C, Shaw H, Bentley RC, Barrett JC, et al. Mutation of the PTEN tumor suppressor gene in endometrial hyperplasias. Cancer Res 1998;58:2500-3.
50. Risinger JI, Hayes AK, Berchuck A, Barrett JC. PTEN/MMAC1 mutations in endometrial cancers. Cancer Res 1997;57:4736-8.
51. Tashiro H, Blazes MS, Wu R, Cho KR, Bose S, Wang SI, et al. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res 1997;57:3935-40.
52. Boyd J, Risinger JI. Analysis of oncogene alterations in human endometrial carcinoma: prevalence of ras mutations. Mol Carcinog 1991;4:189-95.
53. Caduff RF, Johnston CM, Frank TS. Mutations of the Ki-ras oncogene in carcinoma of the endometrium. Am J Pathol 1995;146:182-8.
54. Enomoto T, Inoue M, Perantoni AO, Buzard GS, Miki H, Tanizawa O, et al. K-ras activation in premalignant and malignant epithelial lesions of the human uterus. Cancer Res 1991;51:5308-14.
55. Ignar-Trowbridge D, Risinger JI, Dent GA, Kohler M, Berchuck A, McLachlan JA, et al. Mutations of the Ki-ras oncogene in endometrial carcinoma. Am J Obstet Gynecol 1992; 167:227-32.
56. Sasaki H, Nishii H, Takahashi H, Tada A, Furusato M, Terashima Y, et al. Mutation of the Ki-ras protooncogene in human endometrial hyperplasia and carcinoma. Cancer Res 1993;53:1906-10.
57. Nyholm HCJ, Nielsen AL, Lyndrup J, Norup P, Thorpe SM. Biochemical and immunohistochemical estrogen and progesterone receptors in adenomatous hyperplasia and endometrial carcinoma: correlations with stage and other clinicopathologic features. Am J Obstet Gynecol 1992;167:1334-42.
58. Esteller M, Garcia A, Martinez-Palones JM, Xercavins J, Reventos J. Detection of clonality and genetic alterations in endometrial pipelle biopsy and its surgical specimen counterpart. Lab Invest 1997;76:109-16.
59. Mutter GL, Chaponot ML, Fletcher JA. A polymerase chain reaction assay for non-random X chromosome inactivation identifies monoclonal endometrial cancers and precancers. Am J Pathol 1995;146:501-8.
60. Bulun SE, Economos K, Miller D, Simpson ER. CYP19 (aromatase cytochrome P450) gene expression in human malignant endometrial tumors. J Clin Endocrinol Metab 1994;79: 1831-4.
61. Wantanabe K, Sasano H, Harada N, Ozaki M, Niikura H, Sato S, et al. Aromatase in human endometrial carcinoma and hyperplasia. Immunohistochemical, in situ hybridization, and biochemical studies. Am J Pathol 1995;146:491-500.
62. Cooke PS, Buchanan DL, Young P, Setiawan T, Brody J, Korach KS, et al. Stromal estrogen receptors mediate mitogenic effects of estradiol on uterine epithelium. Proc Natl Acad Sci U S A 1997;94:6535-40.
63. Yager JD, Liehr JG. Molecular mechanisms of estrogen carcinogenesis. Ann Rev Pharmacol Toxicol 1996;36:203-32.
64. Bitterman P, Chun B, Kurman RJ. The significance of epithelial differentiation in mixed mesodermal tumors of the uterus. A clinicopathologic and immunohistochemical study. Am J Surg Pathol 1990;14:317-28.
65. de Brito PA, Silverberg SG, Orenstein JM. Carcinosarcoma (malignant mixed mullerian (mesodermal) tumor) of the female genital tract: immuno-histochemical and ultrastructural analysis of 28 cases. Hum Pathol 1993;24:132-42.
66. Emoto M, Iwasaki H, Kikuchi M, Shirakawa K. Characteristics of cloned cells of mixed mullerian tumor of the human uterus. Carcinoma cells showing myogenic differentiation in vitro. Cancer 1993;71:3065-75.
67. Gorai I, Doi C, Minaguchi H. Establishment and characterization of carcinosarcoma cell line of the human uterus. Cancer 1993;71:775-86.
68. Ambros R, Sherman M, Zahn C, Bitterman P, Kurman RJ. Association of endometrial hyperplasia and endometrial intraepithelial carcinoma and malignant mixed mullerian tumors [abstract]. Mod Pathol 1993;6:72A.
69. Lax SF, Pizer ES, Ronnett BM, Kurman RJ. Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression. Hum Pathol 1998;29:551-8.